Global Lambert-Eaton Myasthenic Syndrome Treatment Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 98

Report ID: 1738

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder involving nerves and muscles that results in significant muscle weakness. It is often associated with certain types of cancer or other autoimmune disorders. It is caused by faulty nerve cells that fail to release sufficient amounts of acetylcholine, the chemical essential for the conduction of impulses between nerves and muscles. There are a number of treatments available for the disorder, but serious complications are possible.
In 2018, the global Lambert-Eaton Myasthenic Syndrome Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Lambert-Eaton Myasthenic Syndrome Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Lambert-Eaton Myasthenic Syndrome Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Allergan, Plc.
Biomarin Pharmaceutical, Inc.
Catalyst Pharmaceuticals, Inc.
F. Hoffman-La Roche Ltd.
GlaxoSmithkline, Plc.
Jacobus Pharmaceutical Company, Inc.
Kawasumi Laboratories, Inc.
Merck & Co., Inc.
Mitsubishi Pharma Corporation

Market segment by Type, the product can be split into
Potassium Channel Blockers (Amifampridine)
Cholinesterase Inhibitor (Pyridostigmine)
Immune Therapy
Intravenous Immunoglobulin
Plasmapheresis

Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Lambert-Eaton Myasthenic Syndrome Treatment status, future forecast, growth opportunity, key market and key players.
To present the Lambert-Eaton Myasthenic Syndrome Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Lambert-Eaton Myasthenic Syndrome Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Size Growth Rate by Type (2014-2025)
1.4.2 Potassium Channel Blockers (Amifampridine)
1.4.3 Cholinesterase Inhibitor (Pyridostigmine)
1.4.4 Immune Therapy
1.4.5 Intravenous Immunoglobulin
1.4.6 Plasmapheresis
1.5 Market by Application
1.5.1 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Share by Application (2019-2025)
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Lambert-Eaton Myasthenic Syndrome Treatment Market Size
2.2 Lambert-Eaton Myasthenic Syndrome Treatment Growth Trends by Regions
2.2.1 Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Regions (2019-2025)
2.2.2 Lambert-Eaton Myasthenic Syndrome Treatment Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Lambert-Eaton Myasthenic Syndrome Treatment Market Size by by Players
3.1.1 Global Lambert-Eaton Myasthenic Syndrome Treatment Revenue by by Players (2014-2019)
3.1.2 Global Lambert-Eaton Myasthenic Syndrome Treatment Revenue Market Share by by Players (2014-2019)
3.1.3 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players Head office and Area Served
3.3 Key Players Lambert-Eaton Myasthenic Syndrome Treatment Product/Solution/Service
3.4 Date of Enter into Lambert-Eaton Myasthenic Syndrome Treatment Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type (2014-2019)
4.2 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application (2014-2019)

5 North America
5.1 North America Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
5.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in North America
5.3 North America Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
5.4 North America Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

6 Europe
6.1 Europe Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
6.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in Europe
6.3 Europe Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
6.4 Europe Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

7 China
7.1 China Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
7.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in China
7.3 China Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
7.4 China Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

8 Japan
8.1 Japan Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
8.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in Japan
8.3 Japan Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
8.4 Japan Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
9.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in Southeast Asia
9.3 Southeast Asia Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
9.4 Southeast Asia Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

10 India
10.1 India Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
10.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in India
10.3 India Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
10.4 India Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

11 Central & South America
11.1 Central & South America Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
11.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in Central & South America
11.3 Central & South America Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
11.4 Central & South America Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

12 International Players Profiles
12.1 Allergan, Plc.
12.1.1 Allergan, Plc. Company Details
12.1.2 Company Description and Business Overview
12.1.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
12.1.4 Allergan, Plc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019))
12.1.5 Allergan, Plc. Recent Development
12.2 Biomarin Pharmaceutical, Inc.
12.2.1 Biomarin Pharmaceutical, Inc. Company Details
12.2.2 Company Description and Business Overview
12.2.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
12.2.4 Biomarin Pharmaceutical, Inc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
12.2.5 Biomarin Pharmaceutical, Inc. Recent Development
12.3 Catalyst Pharmaceuticals, Inc.
12.3.1 Catalyst Pharmaceuticals, Inc. Company Details
12.3.2 Company Description and Business Overview
12.3.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
12.3.4 Catalyst Pharmaceuticals, Inc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
12.3.5 Catalyst Pharmaceuticals, Inc. Recent Development
12.4 F. Hoffman-La Roche Ltd.
12.4.1 F. Hoffman-La Roche Ltd. Company Details
12.4.2 Company Description and Business Overview
12.4.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
12.4.4 F. Hoffman-La Roche Ltd. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
12.4.5 F. Hoffman-La Roche Ltd. Recent Development
12.5 GlaxoSmithkline, Plc.
12.5.1 GlaxoSmithkline, Plc. Company Details
12.5.2 Company Description and Business Overview
12.5.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
12.5.4 GlaxoSmithkline, Plc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
12.5.5 GlaxoSmithkline, Plc. Recent Development
12.6 Jacobus Pharmaceutical Company, Inc.
12.6.1 Jacobus Pharmaceutical Company, Inc. Company Details
12.6.2 Company Description and Business Overview
12.6.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
12.6.4 Jacobus Pharmaceutical Company, Inc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
12.6.5 Jacobus Pharmaceutical Company, Inc. Recent Development
12.7 Kawasumi Laboratories, Inc.
12.7.1 Kawasumi Laboratories, Inc. Company Details
12.7.2 Company Description and Business Overview
12.7.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
12.7.4 Kawasumi Laboratories, Inc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
12.7.5 Kawasumi Laboratories, Inc. Recent Development
12.8 Merck & Co., Inc.
12.8.1 Merck & Co., Inc. Company Details
12.8.2 Company Description and Business Overview
12.8.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
12.8.4 Merck & Co., Inc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
12.8.5 Merck & Co., Inc. Recent Development
12.9 Mitsubishi Pharma Corporation
12.9.1 Mitsubishi Pharma Corporation Company Details
12.9.2 Company Description and Business Overview
12.9.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
12.9.4 Mitsubishi Pharma Corporation Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
12.9.5 Mitsubishi Pharma Corporation Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details